Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin
Authors' conclusion
When combined with basal insulin therapy, exenatide induces an enhanced post-challenge endogenous GLP-1 secretory response following its cessation, with no differential effect on glucagon and GIP secretion.
Study context
- Population
- Adults with T2D
- Participants
- 31 / 32 / 30
- Comparison
- Glargine plus twice-daily exenatide vs glargine plus thrice-daily lispro vs glargine alone
- Glargine (Glar)/Exen = 31
- Glar/Lispron = 32
- Glarn = 30reference
- Primary endpoint
- Endogenous secretion of glucagon, GIP and GLP-1 on 2-hour OGTT (measured every 30 minutes) after stopping therapy
- Follow-up
- 8 weeks
Primary result
As reported in the abstract
Baseline-adjusted GLP-1 AUC on OGTT
- Glar/Exe vs Glar/Lispro, Glar: P = 0.037
Further findings
Baseline-adjusted GLP-1 at 30, 60 and 90 min on oral glucose tolerance test (OGTT) · 8 weeks
- Highest in Glar/Exe at 30 min
- P = 0.037
- Highest in Glar/Exe at 60 min
- P = 0.007
- Highest in Glar/Exe at 90 min
- P = 0.039
GLP-1 concentrations at 30 and 60 min post-challenge · 8 weeks
- Higher with Glar/Exe than other treatments (both)
- P < 0.05
- No differences in fasting GLP-1
Glucagon and GIP · 8 weeks
- Baseline-adjusted AUC for glucagon and GIP between groups (both)
- P = NS
- No differences between groups in response profiles of glucagon and GIP
Original publication
Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin. J Clin Endocrinol Metab. Published 28 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →